DGAP-News: MIG Verwaltungs AG / Key word(s): Dividend
MIG funds increases BioNTech dividend payments to a record €600 million
Munich, Germany, 04 February 2021
Kristian Schmidt-Garve, General Partner of MIG AG, said: "As venture capitalists invested in BioNTech from the very beginning, MIG funds and its clients, have contributed significantly to the development of the company as a leading European biotech. We are proud of our portfolio company's enormous success and their contribution to overcoming the global pandemic with the world's first COVID-19 mRNA vaccine. We are also very pleased that we were able to realize substantial returns for our investors, representing a considerate multiple of their initial investment."
About MIG AG
MIG's investment team consists of a committed group of experts of engineers, biologists, scientists and investors who use analytical and creative processes to evaluate the risks and opportunities of business models and technologies. Their reputation, their experience and their network enable excellent access to companies, institutions and decision-makers to support the growth of their portfolio companies.
In recent years, MIG AG has successfully sold it's portfolio companies SuppreMol (to Baxter in 2015), sunhill technologies (to Volkswagen in 2015), Ganymed (to Astellas in 2016) and Siltectra (to Infineon in 2018) and leads Brain (in 2017), NFON (in 2018), BioNTech (in 2019) and Immatics (in 2020) to listings on stock exchanges.
For further information please visit: www.mig.ag, www.mig-fonds.de
MC Services (for media inquiries)
04.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.